DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

M Reiser; R Schnell; G Straub; P Borchmann; Martin Wilhelm; R Ubelacker; B Wörmann; R Münch; V Diehl; A Engert

doi:10.3109/10428199809059229

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

M Reiser, R Schnell, G Straub, P Borchmann, Martin Wilhelm (Co-Autor/-in), R Ubelacker, B Wörmann, R Münch, V Diehl, A Engert

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

14 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	359-366
Fachzeitschrift	LEUKEMIA & LYMPHOMA
Jahrgang	31
Ausgabenummer	3-4
DOIs	https://doi.org/10.3109/10428199809059229
Publikationsstatus	Veröffentlicht - 1998

Zugriff auf Dokument

10.3109/10428199809059229

Dieses zitieren

Reiser, M., Schnell, R., Straub, G., Borchmann, P., Wilhelm, M., Ubelacker, R., Wörmann, B., Münch, R., Diehl, V., & Engert, A. (1998). DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. LEUKEMIA & LYMPHOMA , 31(3-4), 359-366. https://doi.org/10.3109/10428199809059229

Reiser, M ; Schnell, R ; Straub, G et al. / DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. in: LEUKEMIA & LYMPHOMA 1998 ; Jahrgang 31, Nr. 3-4. S. 359-366.

@article{e73183e762184d5bb1449756a4e0a61a,

title = "DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.",

keywords = "NON-HODGKINS-LYMPHOMA, BONE-MARROW TRANSPLANTATION, HIGH-DOSE CYTARABINE, SALVAGE THERAPY, PHASE-II, AGGRESSIVE-LYMPHOMA, ELDERLY PATIENTS, ARA-C, CHEMOTHERAPY, TOXICITY",

author = "M Reiser and R Schnell and G Straub and P Borchmann and Martin Wilhelm and R Ubelacker and B W{\"o}rmann and R M{\"u}nch and V Diehl and A Engert",

year = "1998",

doi = "10.3109/10428199809059229",

language = "English",

volume = "31",

pages = "359--366",

journal = "LEUKEMIA \& LYMPHOMA ",

issn = "1042-8194",

number = "3-4",

}

Reiser, M, Schnell, R, Straub, G, Borchmann, P, Wilhelm, M, Ubelacker, R, Wörmann, B, Münch, R, Diehl, V & Engert, A 1998, 'DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.', LEUKEMIA & LYMPHOMA , Jg. 31, Nr. 3-4, S. 359-366. https://doi.org/10.3109/10428199809059229

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. / Reiser, M; Schnell, R; Straub, G et al.
in: LEUKEMIA & LYMPHOMA , Jahrgang 31, Nr. 3-4, 1998, S. 359-366.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

AU - Reiser, M

AU - Schnell, R

AU - Straub, G

AU - Borchmann, P

AU - Wilhelm, Martin

AU - Ubelacker, R

AU - Wörmann, B

AU - Münch, R

AU - Diehl, V

AU - Engert, A

PY - 1998

Y1 - 1998

KW - NON-HODGKINS-LYMPHOMA

KW - BONE-MARROW TRANSPLANTATION

KW - HIGH-DOSE CYTARABINE

KW - SALVAGE THERAPY

KW - PHASE-II

KW - AGGRESSIVE-LYMPHOMA

KW - ELDERLY PATIENTS

KW - ARA-C

KW - CHEMOTHERAPY

KW - TOXICITY

U2 - 10.3109/10428199809059229

DO - 10.3109/10428199809059229

M3 - Original Article

C2 - 9869200

SN - 1042-8194

VL - 31

SP - 359

EP - 366

JO - LEUKEMIA & LYMPHOMA

JF - LEUKEMIA & LYMPHOMA

IS - 3-4

ER -

Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. LEUKEMIA & LYMPHOMA . 1998;31(3-4):359-366. doi: 10.3109/10428199809059229